Hemispherx Biopharma, Inc. - 500 Beiträge pro Seite

[js200]

Kennt jemand diese Firma mit diesen WAHNSINNSAUSSICHTEN

09/30/2002 (09:42 ET) Taglich Brothers Announces Investment Opinion: Taglich Brothers Upgrades Hemispherx BioPharma, Inc. to Buy - Business Wire
09/30/2002 (09:09 ET) Taglich Brothers Updated Research Report On Hemispherx Raises Target Price From $13.75 to $25.00 With a Discounted Present Value of $21.08 - Business Wire
09/27/2002 (12:26 ET) 52W LOW: New 52-Wk Low for HEB @ $0.850 dn13.27% - Knobias
09/24/2002 (10:01 ET) 52W LOW: New 52-Wk Low for HEB @ $0.900 dn13.46% - Knobias
09/23/2002 (10:12 ET) 52W LOW: New 52-Wk Low for HEB @ $1.200 dn4% - Knobias

?????????
Hemispherx Biopharma, Inc. (AMEX:HEB)
?????????

JS200

[js200]

company news

--------------------------------------------------------------------------------

HEB - Hemispherx Biopharma, Inc. (AMEX : HEB)

--------------------------------------------------------------------------------
Taglich Brothers Updated Research Report On Hemispherx Raises Target Price From $13.75 to $25.00 With a Discounted Present Value of $21.08

Recommendation Changed to Buy from Speculative Buy; Analyst Andre Garnet Projects Post Approval First Year Revenue`s at $160 Million

MONDAY , SEPTEMBER 30, 2002 09:09 AM

PHILADELPHIA, Sep 30, 2002 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, announced today the issuance of the following research report update by Taglich Brothers senior biotech analyst Andre Garnet.

The full text of the report is available on the Taglich Brothers Website at www.taglichbrothers.com



Highlights of the report reveal the following:
- Recommendation raised to buy from speculative buy
- The target price has been raised from $13.75 to $25.00
- First year revenue after FDA approval for Ampligen`s
indications in HIV/AIDS and Chronic Fatigue Syndrome (CFS) are
projected at $160 million. This is based on a market
penetration of only 0.5%, which Mr. Garnet indicates maybe to
conservative and consequently revenues could be significantly
higher.
- The report expresses the belief that Ampligen has more than a
90% probability of obtaining FDA and European regulatory
approval for both CFS and HIV/AIDS.


Mr. Garnet wrote the report in conjunction with Laura Conroy. Mr. Garnet has covered the Biotech Industry for over 10 years and has a strong track record for discovering undervalued small cap companies within the industry.


About Hemispherx


Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information, including the full text of the abstract described in this press release, please visit the company`s Web site at www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.


CONTACT: Hemispherx Biopharma, Inc.
Investor Relations:
215/988-1712
Fax: [phone]
[e-mail]
Website: www.hemispherx.net
or
MRB Investor Relations, LLC
Wesley Stanton, 212/495-0200, ext. 11
Fax: [phone]
[e-mail]
or
Dianne Will, 518/399-6222
[e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.


JS200

[Alfinanz]

schau mal auf die seite:
http://www.asensio.com/HemispherxBiopharma/HemispherxStory.h…

und viel spass beim lesen ;-)

[js200]

@ALFINANZ

********DANKE ****************

The Hemispherx Story

Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA") with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.

Hemispherx was a defunct company before it was brought public in 1995 by Stratton Oakmont, Inc. Hemispherx was one of Stratton’s last fraudulent initial public offerings ("IPO") before Stratton was shut down for fraudulent sales and trading practices. In fact, Stratton’s principals pled guilty in September 1999 to a number of charges, including using HEB’s IPO to defraud the public. Since its fraudulent IPO, Hemispherx paid U.S. and international stock promoters to create investor demand for its AMEX-listed shares. As of June 30, 2000, Hemispherx’s insiders and stock promoters had bought at least 15,721,560 shares directly from Hemispherx at below market prices, which were then sold to the public at inflated prices. After concluding a preliminary investigation, the U.S. Securities and Exchange Commission commenced a formal securities fraud investigation of Hemispherx’s Ampligen-based stock promotion. The investigation is on going.

A recurring part of Hemispherx’s fraud is the unauthorized use of the names and, by extension, the images of various not-for-profit health advocacy organizations in its press releases. In fact, these groups have specifically objected to being mentioned by HEB as part of its stock promotion. On September 21, 1998, Hemispherx issued a release stating that the CFIDS Network, Inc., a CFIDS patients’ organization, supported Ampligen and considered it a safe drug. However, CFIDS Network President Ronald G. Smith wrote a letter to Dr. William A. Carter, Chairman and Chief Executive Officer of Hemispherx denying any CFIDS Network involvement in the release and accusing Hemispherx of slander. The CFIDS Network then issued a press release stating, "…In our experience, no PWC [person with CFIDS] has received lasting benefits from this medication [Ampligen]. Many suffer from a myriad of side effects." Nevertheless, Hemispherx issued a second press release restating their initial press release and knowingly reiterating their false information.

Hemispherx also announced in press releases that it presented HIV test findings at a conference sponsored by Search For A Cure, ("SFAC") an AIDS not-for-profit organization. SFAC sent a letter to Dr. Carter stating that "Hemispherx did not make a presentation at the conference and its many requests to make a presentation were turned down by SFAC." The SFAC letter further states that "your misstatements are a misuse of the SFAC name and appear to imply an endorsement or legitimacy by association with SFAC, which is untrue." The letter served as a demand for a prominent correction and to cease and desist from further misuse of the SFAC name. Again, Hemispherx ignored the letter and issued another press release making the same false claims.

On May 17, 1999, a group calling itself the AIDS Treatment Technical Assistance Council ("ATTAC") issued a press release over the PR Newswire stating that Ampligen was a clinically promising therapy for HIV. David Miller was named as the Executive Director of ATTAC. We found no record of a non-profit group registered or incorporated under the name ATTAC. The ATTAC press release was paid for by Mitchell Abrahams. Mitch Abrahams is disclosed in a 1999 Hemispherx SEC filing as a recipient of 20,000 privately issued shares of Hemispherx stock.

Ampligen has never received FDA marketing approval. In July 2000, in addition to the October 1998 FDA letter, Hemispherx received two "warning letters" from the FDA. The FDA detailed specific press releases and disclosures made by Hemispherx that constituted promotion of Ampligen as safe and effective in violation of FDA regulations. The FDA stated "your promotional materials are false and misleading in that they fail to disclose facts that are material in light of representations made about Ampligen." In particular, Hemispherx failed to disclose risk information associated with the use of Ampligen. The FDA stated "toxicities that have been reported in dose-escalating studies of Ampligen in HIV-infected patients include, but are not limited to, flushing, chills, fever, chest tightness, nausea, malaise, shortness of breath, flu-like symptoms, leukopenia, neutropenia, and leukocytosis." William A. Carter has also been accused of irregularities and fired from medical research positions at Roswell Park Memorial Institute and even from Hemispherx itself.

On September 21, 1998 Hemispherx announced that it had agreed to invest in California Institute of Molecular Medicine, Inc. ("CIMM"). CIMM was one-year-old. In 1990, Zaki Salahuddin, one of CIMM’s two founders, was indicted by the United States Attorney’s Baltimore office. He pled guilty to felony charges that included funneling contracts to a company partly owned by his wife while he was on staff at the National Cancer Institute. In announcing the partnership Hemispherx stated that it admired Salahuddin’s outstanding achievements but made no mention of his indictment or guilty plea. On February 17, 2000, Hemispherx refers to positive medical findings at CIMM, now an affiliated company, as an alleged reason to claim Ampligen has potential as a treatment for HIV.

A U.S. House of Representatives Subcommittee investigated Carter and his associates for scientific fraud. Carter also has been charged with personally defrauding $1 million from an AIDS patient who sought admission to an Ampligen AIDS trial, which resoundingly failed and was halted. E.I. Du Pont de Nemours and Company (NYSE: DD), which sponsored the failed AIDS trial charged Carter and his colleagues in a lawsuit with scientific fraud.

Another part of Hemispherx’s fraud is the use of legal proceedings to fight opponents. Hemispherx and Dr. Carter have a history of making irregular medical claims and taking legal action against parties that question their claims. Hemispherx repeatedly have filed lawsuits claiming themselves as victims of a series of conspiracies.


JS200

[lux2001]

Hues du dei och,ech gin verreckt.

Salut

[lux2001]

An dat ass vun gechter...

Der Entwickler von immun.de) -basierenden therapeutischen Produkten Hemispherx Biopharma steigt um 30.51 Prozent auf 2.31 Dollar. Taglich Brothers vergaben für die Aktie am Montag ein Kursziel von 25 Dollar. Seither stieg die Aktie von 80 cents um 288 Prozent.

Hemispherx bietet therapeutische Produkte zur Behandlung von HIV (AIDS) und für das chronische Erschöpfungssyndrom (CFS) an.

Die Analysten von Taglich Brothers erhöhten am Montag die Empfehlung für die Aktie von "spekulativ kaufen" auf "kaufen." Das Kursziel wurde von 13.75 auf 25 Dollar erhöht.

Der Umsatz im ersten Jahr durch das Produkt Ampligen für die Anwendungsbereiche HIV und CFS soll im ersten Jahr 160 Millionen Dollar betragen, nimmt man an, dass lediglich eine Marktpenetration von 0.5 Prozent durchzusetzen sei. Taglich Brothers bemisst die Wahrscheinlichkeit einer Marktzulassung für Ampligen in den USA und Europa auf 90 Prozent.

Salut

[MikkaS]

HEMISPHERX BIOPHARMA! Der Kurs konnte in den
vergangenen 4 Tagen knapp 300% zulegen und schloss gestern in New York
bei USD 2.32. HEMISPHERX bietet therapeutische Produkte zur Behandlung
von HIV (AIDS) und für das chronische Erschöpfungssyndrom (CFS) an.
Anfang der Woche kamen die Kollegen von Taglich Brothers mit einer
neuen Kaufstudie in den Markt: Der Umsatz im ersten Jahr durch das
Produkt Ampligen für die Anwendungsbereiche HIV und CFS soll im ersten
Jahr 160 Millionen Dollar betragen, nimmt man an, dass lediglich eine
Marktpenetration von 0.5 Prozent durchzusetzen sei. Taglich Brothers
bemisst die Wahrscheinlichkeit einer Marktzulassung für Ampligen in
den USA und Europa auf 90 Prozent. Demzufolge bekräftigten die
Analysten ihre Kaufempfehlung, erhöhten aber ihr Kursziel kurzerhand
von USD 13.75 auf USD 25! Nochmals: Der aktuelle Kurs von HEMISPHERX
BIOPHARMA liegt bei USD 2.32! Das ist ein utopisch klingendes
Kurspotenzial von annähernd 1000%! Da steckt also eine gehörige
Portion Optimismus drin, aber selbst Kursanstiege in den Bereich
USD 8-12, die wir in den kommenden Monaten durchaus dem Titel
zutrauen, wären satte 250-400% auszuloten!

[js200]

Von Gestern

HEB
HEMISPHERX BIOPHARMA INC
2.150
-0.370 -14.68%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/2/2002 (5) days ago, when the stock price was 1.770. Since then the stock gained 21.47% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick


Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 2.150
Previous Close 2.520
Change -0.370
% Change -14.68%
Volume 448,400
Stock Activity
Open 2.690
Day`s High 2.690
Day`s Low 2.060
52 Week High 5.250
52 Week Low 0.800

Stock Price History
3 Month % Change -17.31
6 Month % Change -41.10
12 Month % Change -46.25
Stock Statistics
50 Day Close MA 1.665
200 Day Close MA 3.022
65 Day Volume MA 63,877

JS200

[Kurumba]

HEPH

[js200]

company news

--------------------------------------------------------------------------------

HEB - Hemispherx Biopharma, Inc. (AMEX : HEB)

--------------------------------------------------------------------------------
Hemispherx Biopharma RNA Drug Technology Pipeline Shows Therapeutic Promise In U.S. Government Sponsored Research

- Specific New Inhibitory Effects Demonstrated on Bioterror-type Agents -

WEDNESDAY, OCTOBER 09, 2002 09:09 AM

PHILADELPHIA, Oct 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- Hemispherx Biopharma, Inc. (Amex: HEB), announced today initial results of a new research collaborative agreement with the National Institutes of Health (NIH) designed to evaluate promising new experimental drug modalities against potential bioterror agents. Hemispherx`s RNA drug technology platform is directed towards potential strengthening of component parts of the body`s immuno-surveillance system and includes both injectible (large molecular weight, e.g., Ampligen(R)) and oral (small molecular weight, e.g., Oragens(TM)) formats of RNA drug technology.

NIH Agreement

As part of the research agreement, the NIH is conducting ongoing animal and laboratory research at its own facilities as well as in contract-sponsored labs including those in Utah and Louisiana that are especially certified for experimentation on unusually hazardous biological agents. The current reports establish biological activity of the Hemispherx products against noxious biological agents, including smallpox, in relevant animal models. All marketing and invention rights accrue to Hemispherx.

New FDA Regulation

In a separate initiative to accelerate research into these biological agents, The Food and Drug Administration (FDA) has recently established new guidelines for commercial approval based on only two (2) animal studies without the necessity for traditional clinical trials.

Promise of RNA Technology

RNA drug technology is a new frontier in development of potential therapy for biological agents and other dreaded viral infections. Recently, Dr. Phillip Sharp, recipient of the 1993 Nobel Prize in Medicine stated, "The RNA interference process is a very new development in biological science and is quite exciting" (http://www.unaids.com ). Obstacles to be solved include identifying ways to deliver specific RNAs to animals and humans with minimal disruption to normal biological process. Hemispherx also sponsors related research in the European Union.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company`s Web site at http://www.hemispherx.net .

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.



MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X32428769


SOURCE Hemispherx Biopharma, Inc.


CONTACT: Investor Relations of Hemispherx Biopharma, [phone],
Fax - [phone], [e-mail]; or Robin Wagge of Rubenstein
Associates, Inc., [phone], [e-mail], for Hemispherx
Biopharma

URL: http://www.hemispherx.net
http://www.prnewswire.com



Copyright (C) 2002 PR Newswire. All rights reserved.


-0-


KEYWORD: Pennsylvania
INDUSTRY KEYWORD: HEA
MTC
BIO


STOCK SYMBOLS: [(heb)]


JS200